Search the site

People

Dr Ruth Thornton

Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG)

News & Events

The Kids researchers help quantify global impact of life-saving vaccines

Researchers at The Kids Research Institute Australia have helped map the global impact of life saving vaccines to mark the 50-year anniversary of the Expanded Programme on Immunisation (EPI).

News & Events

WA parents oblivious to true danger of the flu

Perth parents are underestimating the serious consequences of the flu, with only 19 per cent of children under five years of age currently immunized against the virus ahead of the peak winter flu season.

News & Events

The Kids Research Institute Australia researchers share in TPCHRF funding

Eight The Kids Research Institute Australia researchers are among those who have received grant funding from the Telethon-Perth Children’s Hospital Research Fund (TPCHRF).

News & Events

Vaccine trial aims to curb ‘superbug’

Sarah Le Roi knows well how debilitating Clostridium difficile infection (CDI) can be. She was struck down with the 'superbug' while on holiday in the US.

News & Events

Wesfarmers Centre of Vaccine and Infectious Diseases Research Seminar Series 2014

Wesfarmers Centre of Vaccine and Infectious Diseases Research Seminar Series 2014.Genetic and functional studies of leishmaniasis: understanding the role of HLA

News & Events

Infectious Disease & Vaccination Public Seminar

Hear the facts about vaccination and infectious disease from some of Australia's leading experts: Professor Jonathan Carapetis, Dr Peter Richmond

News & Events

WANTED: 'Flu Busters

Hundreds of healthy volunteers are needed in Perth to test the effectiveness of a current 'flu vaccine.

News & Events

Deborah Lehmann Research Award Opportunity

The Deborah Lehmann Research Award in Paediatric Infectious Disease Research is a funding mechanism to support the training and development of early- to mid-career researchers (EMCR) or Higher Degree by Research (HDR) students who are nationals from the Pacific Region working in or outside their hom

Research

Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study

Since 1955, the recommended strategy for rheumatic heart disease secondary prophylaxis has been benzathine penicillin G injections administered intramuscularly every 4 weeks. Due to dosing frequency, pain, and programmatic challenges, adherence is suboptimal. It has previously been demonstrated that BPG delivered subcutaneously at a standard dose is safe and tolerable and has favorable pharmacokinetics, setting the scene for improved regimens with less frequent administration.